Woods International LLC

Woods International LLC, a service-disabled veteran-owned small business (SDVOSB) and veteran-owned small business (VOSB) based in Riverview, Florida, supplies pharmaceutical products and medical supplies to the federal government as a prime contractor, operating predominantly under small business set-asides and sole-source SDVOSB awards. The company is minority-owned and Black American-owned, with both SDVOSB and VOSB certifications expiring May 3, 2026.

Woods International's capability footprint is entirely pharmaceutical and medical supply distribution. The vendor specializes in supplying individual pharmaceutical line items and multi-line drug orders to the Department of Veterans Affairs Consolidated Mail Outpatient Pharmacy (CMOP) network nationwide, with secondary work for the Department of Health and Human Services Office of the Assistant Secretary for Administration. Representative awards include a $2.299 million sole-source SDVOSB delivery of Tamsulosin HCl 0.4 mg capsules to VISN 15 (August 2024), a $229.432 million full-and-open order for seven-line over-the-counter pharmaceutical requirements across multiple CMOP locations to VISN 15 (May 2024), a $257.870 million small business set-aside for Rifampin 300 mg capsules to HHS (August 2023), and a $215.902 million small business set-aside for Timolol Maleate 0.5% ophthalmic solution to VISN 15 (February 2023). The vendor also executes smaller purchase orders ranging from five thousand to one hundred twenty thousand dollars for individual pharmaceutical products such as Diazepam, Propranolol HCl, Zolpidem Tartrate, Armodafinil, and Bariatric Multivitamin formulations.

Customer concentration is extreme. The top five Veterans Integrated Service Networks account for 90% of all awards by count and 94% of combined potential value. VISN 15 alone anchors 40 awards valued at $3.6 million — more than half of the vendor's entire portfolio. VISN 12, VISN 22, and VISN 7 contribute $1.1 million, $807 thousand, and $630 thousand respectively. HHS represents the only significant non-VA customer, with three awards worth $520 thousand. Woods International operates no parent vehicles, GWACs, or BPAs; all awards are direct purchase orders issued by individual VA networks and HHS.

Activity has held relatively flat over five years (2022: 4 awards, 2023: 10, 2024: 13, 2025: 6, 2026: 3) with combined potential value of $7.1 million and combined obligated dollars matching that ceiling at one hundred percent. The vendor carries no subcontract footprint — all 116 awards are prime awards with zero sub-work. Set-aside posture splits between total small business set-asides (roughly 70% of awards) and unrestricted full-and-open competitions (roughly 20%), with a small cadre of sole-source SDVOSB awards representing the highest-dollar single line items. NAICS concentration is decisive: 104 of 116 awards fall under Pharmaceutical Preparation Manufacturing (NAICS 325412), with 11 awards under In-Vitro Diagnostic Substance Manufacturing and one under Surgical and Medical Instrument Manufacturing. PSC data mirrors this — 102 awards under Drugs and Biologicals, 14 under Medical and Surgical Instruments, Equipment, and Supplies.

The recompete exposure is material. Of the 116 awards in the source portfolio, multiple high-dollar items reached ultimate completion dates between October 2024 and March 2026, with cumulative recompete risk concentrated in the VISN 15 and VISN 7 networks where Woods International has dominant share. The Tamsulosin contract (awarded August 2024, completed December 2024) represents the single largest award and is now subject to recompete. Woods International's entire federal footprint reflects a hyperspecialized pharmaceutical supply model targeting VA CMOP consolidation — the company maintains no consulting, services, or non-pharmaceutical product lines in federal work.